Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Jazz, With New Patent, Expands Fight on Avadel’s Narcolepsy Drug

Aug. 5, 2021, 4:04 PM

Jazz Pharmaceuticals expanded its courtroom battle seeking to block sales of Avadel’s proposed once-nightly narcolepsy drug, which Jazz said infringes a patent issued Tuesday related to its drug Xyrem.

  • Jazz is seeking court order blocking Avadel from making or selling its product, a branded drug currently known as FT218, and cash compensation if it does so before patent has expired, according to complaint filed Wednesday in federal court in Wilmington, Delaware
  • Patent was issued Tuesday and covers methods of use and administration of drug compositions containing sodium oxybate, the active ingredient in Jazz’s twice-nightly Xyrem
    • Patent covers formulation of, ...